Conventional cancer treatments and diagnosis, such as surgery, radiotherapy, chemotherapy, biopsy, and X-rays have been used for decades to detect cancer and to treat the patients who suffer from the malady symptoms, however the conventional cancer treatment is harmful to healthy cells, and the conventional cancer detection is not sufficiently sensitive, because it is possible only after substantial growth of cancerous cells. Novel strategies for the treatment and detection of cancer, such as Nanotechnology may greatly enhance the cure opportunities for patients and improve the quality of their life by minimizing the toxic effects of anticancer drugs. In the Nanotechnology methods, such as Sodium Chloride Nanoparticles (SCNPs), Liposomes, Magnetic Nanoparticle (MNPs), Quantum Dots (QDs), and Gold Nanoparticles (AuNPs), the nanoparticles can be designed and formulated to create therapeutic agents that targeting the cancerous cells. In this review, the details of these possi-ble detection, diagnosis and treatment methods of nanotechnology are discussed carefully.

No abstract

No abstract

No abstract

Beta thalassemia (β-thal) is one of the most common worldwide inherited hemoglobinopathies. Proper identification and diagnosis of hemoglobin (Hb) variants provide a major challenge. In this report, we describe a 1-year-old boy, presented with the diagnosis of β-TM (beta thalassemia major), has received regular blood transfusions. The molecular analysis revealed the presence of rare Hb Castilla [Beta 32(B14) Leu>Arg; HBB: c.98T>G] variant associated with β0 [IVS-I-1 (G>A); AG^GTTGGT- >AGATTGGT beta0] (HBB:c.92+1G>A) Mutation in beta-globin (β-globin) gene. To our knowledge, this is the first report of Hb Castilla [Beta 32(B14) Leu>Arg] in ExonII of β-globin gene which were found in Syrian male proband. However, we should investigate abnormal hemoglobins in patients with beta thalassemia to determine whether they have involvement with β-thalassemia mutations in the clinical case of the patients or not.